# Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

> **NCT00623766** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 99 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Corticosteroid: Betamethasone
- **DRUG:** Corticosteroid: Dexamethasone
- **DRUG:** Corticosteroid: Fludrocortisone
- **DRUG:** Corticosteroid: Hydrocortisone
- **DRUG:** Corticosteroid: Meprednisone
- **DRUG:** Corticosteroid: Methylprednisolone
- **DRUG:** Corticosteroid: Prednisolone
- **DRUG:** Corticosteroid: Prednisone
- **DRUG:** Corticosteroid: Triamcinolone

## Key facts

- **NCT ID:** NCT00623766
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-09
- **Final completion:** 2012-10
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2014-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00623766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00623766, "Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00623766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*